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Many events during pregnancy and early infancy can affect infant brain
development. Inflammation during pregnancy, around delivery and during early infancy
appears to adversely affect infant brain development. As the brain is rapidly growing and
developing from conception through early childhood, it is particularly vulnerable during this
time to inflammatory insults, which may be exacerbated or ameliorated by nutritional
factors. Inflammatory compounds, as well as many nutritional compounds, can be either
pro- or anti-inflammatory. These compounds are of particular importance in preterm
infants, who are at risk of deficiency in anti-inflammatory micronutrients typically stored as
a result of prenatal maternal diets and thus reliant on post-natal dietary supplementation.
Understanding the ways in which nutritional status and inflammation interact with each
other has been identified as a key gap to fill in improving our ability to treat and prevent
neurodevelopmental impairment as a result of prematurity. We examined the innovative
conceptual framework by which nutritional compounds such as alpha- and beta-carotenes,
lutein, lycopene and alpha-tocopherol are associated with decreased levels of proinflammatory compounds associated with inflammation in utero and after delivery. These
studies will lay the foundation for long-term studies of neurodevelopment outcomes in
these infants, as well as allow us to identify key pathways we might target for dietary or
pharmacologic immunomodulation to improve neurologic outcomes in high risk infants.
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CHAPTER ONE: INTRODUCTION

Almost 10% of infants in Nebraska are born prematurely, or preterm, before 37
weeks gestation1. As healthcare has advanced, the number of these infants that survive
the neonatal period has increased; however, the rates of neurodevelopmental impairment
that occur in these infants have not decreased2. Depending on gestational age and
birthweight, 30-60% of preterm infants have neurodevelopmental impairments that persist
into later childhood, including visual problems, cerebral palsy, developmental delays and
problems with school function2-6. Understanding the factors that have the greatest impact
on development can lead to treatment and prevention strategies that improve health for
children throughout the United States and the world.

Inflammation and Neurodevelopment.
Many events during pregnancy and early infancy can affect infant brain
development. The time from conception through early childhood is sometimes referred to
as the “1000 days critical window” because of the rapid anatomic and functional changes
in the developing brain at this age7. There is increasing evidence that inflammation in early
development, from intrauterine, peri-partum and early childhood insults, may have lifelong
impacts on neurologic function8,9. For example, elevated pro-inflammatory compounds in
cord blood have been associated with an increased risk of cerebral palsy in several case
series8,9. Animal studies attempting to better define the impact of specific inflammatory
processes on neurologic function have demonstrated that cytokine exposure during
infancy increases the risk for changes in memory or neuropsychiatric function later in life
following a second immune challenge10-13. Additionally, following E. coli sepsis, rodents
are less responsive to cognitive enrichment strategies than those without a history of
infection10. Importantly, these effects are only observed in rodents less than 30 days of
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age, revealing an early period of vulnerability in the developing brain10,12. In addition to
risks with pro-inflammatory

cytokines, anti-inflammatory cytokines may provide a

balancing protective effect. My animal work in adult and infant mice with central nervous
system (CNS) infections has identified a role for the potent anti-inflammatory cytokine
interleukin-10 (IL-10) in neuroprotection following S. epidermidis catheter infection in the
brain14. As both CNS and peripheral inflammation are associated with neurologic
sequelae, it is possible that IL-10 serves a similar protective function in both systemic and
CNS infections, as well as other stressors. While IL-10 and other cytokines have been
evaluated as possible biomarkers for infection in infants, these studies have not taken into
the gestational age of the infant nor the association of these immunologic responses with
potentially immunomodulatory nutritional factors15,16.

Dietary Modulation of Inflammation.
As the brain is rapidly growing and developing from conception through early
childhood, it is particularly vulnerable during this time to inflammatory insults, which may
be exacerbated or ameliorated by nutritional factors7. This is of particular importance in
preterm infants, who are at risk of deficiency in anti-inflammatory micronutrients typically
stored as a result of prenatal maternal diets and thus reliant on post-natal dietary
supplementation17. Without antioxidants to balance the effects of oxidative stress and
inflammation,

infants are at risk of abnormalities

bronchopulmonary

dysplasia,

and retinopathy

in neurologic

of prematurity18.

development,

Major nutritional

antioxidants include alpha- and beta-carotenes, lutein, lycopene, and alpha-tocopherol19 .
Infants must acquire these compounds through dietary sources as humans cannot
synthesize these compounds18,19. Vitamin E, in particular, occurs in both an alpha- and
gamma-tocopherol

isoform19. While alpha-tocopherol has anti-inflammatory

effects,

gamma-tocopherol is conversely and potently pro-inflammatory19. Thus, the balance of
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these two compounds could have important implications for regulating inflammation and
thereby affecting neonatal development but have not been previously defined. At a recent
National Institute of Child Health and Human Development (NICHD) meeting on
“Research Gaps at the Intersection of Child Neurodevelopment,

Nutrition, and

Inflammation in Low-Resource Settings,” understanding of the ways in which nutritional
status and inflammation interact with each other and with neurodevelopment was
identified as the first key gap to fill in improving our ability to treat and prevent
neurodevelopmental impairment as a result of prematurity20. To fill this gap, we will
evaluate the relationship between pro- and anti-inflammatory cytokines, nutritional proand antioxidants in term and preterm infants.

Conceptual Framework
We propose the innovative conceptual framework by which nutritional compounds
such as alpha- and beta-carotenes, lutein, lycopene, and alpha-tocopherol reduce proinflammatory compounds associated with inflammation in utero and after delivery, which
may result in improved neurologic outcomes in the future (Figure 1). By countering these
pro-inflammatory compounds directly through anti-oxidant activities and indirectly by
increases in anti-inflammatory IL-10, these nutritional compounds may improve the
neurologic outcomes of premature infants. As premature infants are known to have lower
levels of these protective nutritional compounds17, strategies to both improve maternal diet
and to provide post-natal supplementation may serve to increase levels of these
compounds and improve neurologic outcomes. In this study, we have evaluated maternal
and neonatal levels of pro- and anti-inflammatory compounds (such as interleukin-1β,
tumor necrosis factor-α, interleukin-6, interleukin-8, interleukin-2, and IL-10) and
nutritional compounds (such as lutein, + zeaxanthin, β-cryptoxanthin, trans-lycopene, cislycopene, total lycopene, α-carotene, trans-β-carotene,
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Figure 1: Proposed model of inflammatory modulation and neurologic outcomes
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cis-β-carotene, total-β-carotene, retinol, α-tocopherol, and γ-tocopherol) to examine their
interactions with each other in term and pre-term infants.

Hypothesis
The hypothesis of this proposal is that nutritional compounds such as alpha- and
beta-carotenes, lutein, lycopene, and alpha-tocopherol are associated with lower levels of
pro-inflammatory compounds associated with inflammation in utero and after delivery,
which may result in improved neurologic outcomes in the future.

Clinical Impact of this Research
A better understanding of the relationship between inflammation and nutrition
would present several clinical advantages. Nutritional compounds may have significant
effects on neurologic development through pro- and antioxidant activities and could be
targeted through pre- and post-natal dietary interventions. This information could also be
exploited to allow for earlier identification of infants at risk for neurodevelopmental
disorders or other adverse inflammatory outcomes due to dietary insufficiencies during
these crucial periods. These patients may require more aggressive or specifically targeted
behavioral therapies in addition to nutritional supplementation to improve overall clinical
outcomes. Thus, defining the factors that shape the inflammatory response in infants has
the potential to significantly impact the health of neonates and infants.
This is the first study to describe the association between pro- and antiinflammatory compounds and nutritional compounds in term and preterm infants. While
some adult studies have demonstrated an inverse relationship between levels of vitamins
C, E and D, and inflammatory markers, studies in infants are lacking21. As noted
previously, evaluation of these associations in infants is of critical importance given the
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increased susceptibility of preterm infants to neurologic

injury associated with

inflammation and nutritional deficiencies at birth that may exacerbate inflammation.
Additionally, other micronutrients such as zeaxanthin, β-cryptoxanthin, trans-lycopene,
cis-lycopene, total lycopene, α-carotene, trans-β-carotene, cis-β-carotene, total-βcarotene, and retinol have not been evaluated to determine their impact on systemic
inflammation. Studying the associations between these nutritional compounds and
inflammation may identify targets for pre- and post-natal dietary interventions in future
clinical trials. Immunologic profiling may also allow us to risk-stratify infants in terms of
long-term neurologic development, with those displaying a more neuroprotective IL-10
predominant response or higher levels of α-tocopherol having better long-term outcomes.
This may also provide an immunomodulatory target in the future, by targeting components
of the IL-10 pathway or dietary interventions.
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CHAPTER TWO: METHODS
Design
This cross-sectional, descriptive study will evaluate the association between proand anti-inflammatory cytokines and nutritional antioxidants and pro-oxidants in term and
pre-term infants. We will utilize existing samples from a cohort of 122 mother-infant pairs,
which includes cord blood (infant) and maternal blood collected at birth.

Enrollment and Initial Sample Collection
Mothers of infants admitted to the neonatal intensive care unit (NICU) were
approached for consent and enrollment in this study in summer 2016 and summer 2017.
A maternal blood and cord blood sample were obtained from each infant enrolled.
Maternal and cord blood samples are routinely drawn by the nursing staff during each
delivery at Nebraska Medicine. After it was determined that the entire cord blood sample
and a maternal blood sample was not needed for clinical purposes, it was collected by
study personnel in subjects that have consented to participate in the study. This study was
approved by the University of Nebraska Medical Center Institutional Review Board,
Protocol 112-15-EP, Fatty Acids, Fat Soluble Vitamins, Infant Feeding and Inflammation
during NICU Hospitalization.

Inflammatory and Nutritional Compound Analysis
Pro- and anti-inflammatory cytokine levels will be measured via a commercially
available multi-analyte bead array (Millipore) per the manufacturers' instructions. This will
include testing for interleukin-1β (IL-1β), tumor necrosis factor-α (TNF-α), interleukin-6 (IL6), interleukin-8 (IL-8), interleukin-10 (IL-10), and interleukin-2 (IL-2). Superoxide
dismutase (SOD), an endogenous anti-oxidant enzyme that plays a role in the anti-
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inflammatory effects of some nutritional compounds22, was measured in maternal and
infant samples using the SOD assay kit-WST (WST-1, 2-(4-Iodopheny)-3-(4-nitropheny l)5-(2,4-disulfophenyl)-2H-tetrazolium,

monosodium salt) from Dojindo23. This assay

measures the percent inhibition of WST reduction by SOD, with one unit of SOD
representing the amount of enzyme in 20µL of the sample that results in a 50% reduction
of WST-123. These cytokine levels were selected as they have been previously proposed
to correlate with neurologic outcomes or have potential neuroprotective anti-inflammatory
effects

8,24,25

. Serum nutrient levels will be assessed in the Biomarker Research Institute

at Harvard University.

Measurements of lutein + zeaxanthin, β-cryptoxanthin, trans-

lycopene, cis-lycopene, total lycopene, α-carotene, trans-β-carotene, cis-β-carotene,
total-β-carotene, retinol, α-tocopherol, and γ-tocopherol will be obtained. Concentrations
of α- and gamma-tocopherol in plasma samples will be measured by high-performance
liquid chromatography as previously described by Hanson, et al

19

. As outlined above,

these nutritional compounds were selected based on their potential pro- and antioxidant
properties; however, this not been previously studied in infants18,19. These analyses will
allow us to investigate the proposed aims investigating the association between pro- and
anti-inflammatory cytokines with pro- and anti-oxidant nutritional compounds in infants and
in mother-infant pairs. We expect that levels of maternal and/or infant anti-inflammatory
nutritional compounds (as outlined in Table 1) are inversely correlated with levels of proinflammatory compounds. We will additionally determine if levels of pro-oxidant nutritional
compounds, such as γ-tocopherol, are associated with increases in pro-inflammatory
cytokines and similarly if levels of anti-oxidant nutritional compounds are associated with
an increase in anti-inflammatory IL-10.
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Clinical Data and Evaluation
Demographic and clinical data will be collected from the mother and infant's record
at delivery, including gestational age, birth weight, length, head circumference, race,
ethnicity, maternal chorioamnionitis, maternal infections, maternal smoking/drug use,
prenatal complications, Apgar scores and neonatal complications including seizures,
infections, intraventricular hemorrhage, and respiratory distress syndrome (Table 2).
Prenatal clinical measures, such as maternal infections and complications, and
demographic factors such as race and ethnicity will be assessed as potential confounders
affecting the association between nutritional compounds and cytokine responses. Postnatal outcomes, such as birth weight, length, and head circumference, Apgar scores and
neonatal complications will be evaluated as outcomes potentially associated with
increased levels of these nutritional compounds and cytokines. Gestational age, with
prematurity defined as a gestational age less than 37 weeks and 0 days at the time of
delivery, will also be included in analysis to determine if prematurity independently affects
the association between nutritional compounds and inflammatory responses, suggesting
that the altered immunity of a preterm infant may not respond in the same ways to
nutritional manipulation as a more mature immune system.

Data Analysis Plan
This is a cross-sectional, descriptive study to collect pilot data for future NIH
funding applications. All analyses were conducted using the intent-to-treat criterion.
Descriptive statistics such as the mean, median, standard deviation, 95% CI, and range
were used to summarize each outcome variable.26 As the data are not normally distributed,
the Wilcoxon-Mann-Whitney test was used to compare medians between smokers and
non-smokers,

term and pre-term infants, and infants with pre- and post-natal

complications. The nutritional and inflammatory compounds are continuous variables and
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Pro-inflammatory compounds
IL-1β
TNF-α
IL-6
IL-8
γ-tocopherol

Anti-inflammatory compounds
IL-10
IL-2
Lutein + zeaxanthin
β-cryptoxanthin
trans-lycopene, cis-lycopene, total
lycopene
α-carotene, trans-β-carotene, cis-βcarotene, total-β-carotene
Retinol
α-tocopherol
Superoxide dismutase

Table 1: Proposed pro- and anti-inflammatory dietary and immune compounds for
evaluation.
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Potential Confounder/
Mediator / Moderator
Prenatal Complications: Maternal
chorioamnionitis, infection, others
Maternal drug/tobacco use
Gestational age
Prematurity *
Race/ethnicity

Secondary Outcome Measure
Birth weight
Birth length
Head circumference
Apgar scores
Neonatal complications: Seizures,
infection, others

Table 2: Clinical and demographic factors that may be associated with inflammatory
and nutritional compounds. * Prematurity defined as gestational age less than 37 days
and 0 days.
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differences between compounds were evaluated using Wilcoxon rank sum as the data
points were not normally distributed. Associations between compounds were evaluated
via Spearman correlation coefficients, with hypothesis testing via Fisher's z-transformation
to test the differences in the strength of this correlation in term versus pre-term infants27.
We also used Fisher’s z-transformation to test the differences in the strength of the
correlation in infants born to mothers with current or prior tobacco use in comparison with
those with no smoking tobacco history. The demographic and clinical data outlined above
were evaluated as potential confounders affecting the association between nutritional
compounds and cytokine responses, and we utilized multiple regression to address the
effects of these factors on the observed relationships between inflammatory compounds
and nutritional compounds. Because there were very few participants with documented
prenatal complications, this was treated as a single variable defined as “prenatal
complication”

to

include:

pre-eclampsia,

maternal

diabetes,

suspected

clinical

chorioamnionitis, placental evidence of chorioamnionitis and premature rupture of
membranes. To evaluate the relationship between the nutritional compounds and cytokine
responses and the neonatal complications, the Mann-Whitney-U-test was used as the only
neonatal complication documented was respiratory distress syndrome (RDS) and the
cytokine data is not normally distributed.26,

28

p < 0.05 will be considered statistically

significant. For all twin deliveries, only twin A was included in the analysis to avoid overrepresentation of twin infants in subsequent analyses. All statistical analyses were
performed using Excel, SPSS, and VassarStats.
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CHAPTER THREE: RESULTS

Description of Participants
One hundred and twenty-two maternal-infant pairs are included in this analysis,
based on the availability of paired maternal and infant blood samples. This includes 120
singleton deliveries and two twin deliveries. As noted above, in the instance of twin
deliveries, only the samples from twin A are included in future analyses. There are more
male than female infants included in these analyses (n=74; 57.8% male; n=48; 37.5%
female) (Table 3). 85 infants (66.4%) were delivered to Caucasian mothers; 19 African
American mothers (14.8%); 7 Hispanic mothers (5.5%); 3 Asian or Pacific Islander (2.3%);
1 Native American (0.8%) and 7 unknown or unreported (5.5%) (Table 3).
This data set includes 14 (11.5%) preterm deliveries, defined as less than 37
weeks and 0 days estimated gestational age, and 15 deliveries (11.7%) with prenatal
complications, as outlined in Table 3. Prenatal complications included maternal diabetes
(n=8), suspected clinical chorioamnionitis (n=1), placental chorioamnionitis (n=1), preeclampsia (n=2) and premature rupture of membranes (n=5). Current or former maternal
smoking was common, with 19 mothers (14.8%) reporting current tobacco use in this
pregnancy and 28 (21.9%) reporting former tobacco use (Table 3).

Neonatal Complications

Ten of the pregnancies included in this dataset resulted in neonatal complications
(7.85), including respiratory distress syndrome (n=10, 7.8%). There were no cases of
retinopathy of prematurity, bacteremia as evidenced by positive blood cultures,
intraventricular hemorrhage or necrotizing enterocolitis documented in this dataset.
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Characteristic
Gender

n (% total)
Male 74 (61%)
Female 48 (39%)

Race/Ethnicity
White
African American
Hispanic
Asian / Pacific Islander
Native American
Other/Unknown

85 (66.4%)
19 (14.8%)
7 (5.5%)
3 (2.3%)
1 (0.8%)
7 (5.5%)

Prematurity
Term 108 (88.5%)
Pre-term 14 (11.5%)
Prenatal Complications
Maternal diabetes
Clinical chorioamnionitis
Placental Chorioamnionitis
Pre-eclampsia
Premature rupture of membranes
Maternal Tobacco
No prior tobacco use
Current tobacco use
Former tobacco use
Neonatal Complications
Retinopathy of Prematurity
Intraventricular Hemorrhage
Necrotizing enterocolitis
Bacteremia
Respiratory Distress Syndrome

8 (6.6%)
1 (0.8%)
1 (0.8%)
2 (1.6%)
5 (4%)
74 (57.8%)
19 (14.8%)
28 (21.9%)
0
0
0
0
10 (8.2%)

Table 3: Description of the participating mother-infant pairs in this study (N=122).

15
Characteristic
Gestational age (weeks)
Birth weight (grams)
Birth weight percentile
Birth head
circumference (cm)
Birth head
circumference
percentile
Birth length (cm)
Birth length percentile
Apgar 1 minute
Apgar 5 minute

Median (Q1, Q3)
39.57 (38.57, 40.43)
3458.5 (3050.75, 3744)
65.54 (36.38, 80.62)
34.9 (33.7, 35.6)

Range
25-42.13
860-4617
3.26-99.82
24-47.6

50 (48.3, 52.1)

32-55.2

49.25 (32, 52.1)
68.57 (29.62, 87.59)
8 (7, 8)
9 (9, 9)

32-55.2
0.01-99.77
1-9
3-10

Table 4: Description of study population birth characteristics. Data are presented as
medians, with first (Q1) and third (Q3) quartiles noted because data were not normally
distributed.
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Median Apgar scores were 8 at 1-minute (range 1-9) and 9 at 5-minutes (range 3-10)
(Table 4).

Maternal and Infant Inflammatory Compounds

Infant cord blood samples were noted to have higher levels of most inflammatory
compounds measured, except for IL-2 which was slightly higher in the maternal samples
(Table 5, Figure 2). Superoxide dismutase was measured in only 27 infant and 22
maternal samples as this was an exploratory measure added later in the study. Infant
superoxide dismutase activity was also higher than maternal, with a median of 431.74
U/mL (range 176.62-1234.21) in infant samples and 172.77 U/mL (range 62.5-974.35) in
maternal samples. There was no significant correlation between gestational age and any
of the inflammatory compounds measured. As noted in Tables 6-7, there are significant
correlations between many maternal and infant inflammatory compounds, reflecting the
significant cross-talk between various components pro- and anti-inflammatory of the
immune response. Because the primary focus of this project is the relationship between
inflammatory compounds and nutritional compounds, subsequent analysis and results
focus on this relationship. However, the factors that influence the correlation between
cytokines in infancy will be analyzed in future studies of this dataset.
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Cytokine (pg/mL)
Infant samples
IL-10
IL-1β
IL-2
IL-6
IL-8
TNF-α
Maternal samples
IL-10
IL-1β
IL-2
IL-6
IL-8
TNF-α

Median (Q1, Q3)

Range

21.85 (12.26, 32.11)
8.52 (5.50, 12.18)
5.72 (3.94, 10.54)
13.72 (5.35, 50.82)
12.99 (7.36, 29.66)
52.12 (42.52, 64.96)

2.94-472.95
0-133.74
2.29-21.82
0-1997
3.14-1325
16.39-298.79

14.78 (7.68, 24.83)
6.3 (4.24, 10.21)
7.43 (4.78, 10.96)
11.05 (6.63, 46.16)
7.84 (4.96, 16.285)
25.18 (17.42, 35.95)

-2e+308-105.42
-2e+308-20.08
2.55-216.75
3.07-216.75
-2e+308-125.25
-2e+308-473.96

Table 5: Median infant and maternal cytokine measurements (pg/mL). IL-10, IL-1β,
IL-2, IL-6, IL-8, and TNF-α levels were measured in all 122 samples.
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Maternal and Infant Inflammatory
Compounds
60

*

50
40
30

*

20

*

*

10
0
IL10

IL1B

IL2
Infant

IL6

IL8

TNFa

Maternal

Figure 2: Maternal and Infant Cytokines. Median levels of infant (black) and maternal
(grey) inflammatory compounds (pg/mL). N=122. * p <0.05
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Inflammatory Compound Correlation
with other Inflammatory Compound
Infant IL-10
Infant IL-10: Infant IL-1β
Infant IL-10: Infant IL-2
Infant IL-10: Infant IL-6
Infant IL-10: Infant TNF-α
Infant IL-10: Maternal Superoxide
Dismutase
Infant IL-1β
Infant IL-1β: Infant IL-10
Infant IL-1β: Infant IL-2
Infant IL-1β: Infant TNF-α
Infant IL-1β: Maternal IL-10
Infant IL-1β: Maternal TNF-α
Infant IL-2
Infant IL-2: Infant IL-10
Infant IL-2: Infant IL-1β
Infant IL-2: Infant TNF-α
Infant IL-2: Maternal IL-10
Infant IL-2: Maternal TNF-α
Infant IL-6
Infant IL-6: Infant IL-10
Infant IL-6: Infant IL-8
Infant IL-6: Infant TNF-α
Infant IL-6: Maternal IL-6
Infant IL-6: Maternal IL-8
Infant IL-8
Infant IL-8: Infant IL-6
Infant IL-8: Infant TNF-α
Infant IL-8: Maternal IL-6
Infant IL-8: Maternal IL-8
Infant IL-8: Infant Superoxide Dismutase
Infant TNF-α
Infant TNF-α: Infant IL-10
Infant TNF-α: Infant IL-1β
Infant TNF-α: Infant IL-2
Infant TNF-α: Infant IL-6
Infant TNF-α: Infant IL-8
Infant TNF-α: Maternal IL-6
Infant TNF-α: Maternal Superoxide
Dismutase

rs (95% confidence interval)

0.452
0.451
0.324
0.312
0.477

(0.298
(0.297
(0.155
(0.142
(0.327

to 0.583)
to 0.582)
to 0.474)
to 0.464)
to 0.604)

0.452 (0.298 to 0.583)
0.849 (0.791 to 0.892)
0.357 (0.191 to 0.503)
0.250 (0.076 to 0.41)
0.266 (0.093 to 0.424)
0.451 (0.297 to 0.582)
0.849 (0.791 to 0.892)
0.387 (0.225 to 0.528)
0.231 (0.056 to 0.393)
0.234 (0.059 to 0.395)
0.324
0.797
0.302
0.387
0.341

(0.155
(0.721
(0.131
(0.225
(0.174

to 0.474)
to 0.854)
to 0.455)
to 0.528)
to 0.489)

0.797
0.290
0.349
0.219
0.463

(0.721
(0.118
(0.183
(0.043
(0.311

to 0.854)
to 0.445)
to 0.496)
to 0.382)
to 0.592)

0.312
0.357
0.387
0.302
0.290
0.231
0.440

(0.142
(0.191
(0.225
(0.131
(0.118
(0.056
(0.284

to 0.464)
to 0.503)
to 0.528)
to 0.455)
to 0.445)
to 0.393)
to 0.573)

Table 6: Correlation between maternal and infant cytokines (infant). Spearman's
correlation coefficients (rs) were calculated for all inflammatory compounds in both infant
and maternal samples (N=122). Significantly significant (p <0.05) relationships are
included in this table. Other relationships were not statistically significant.
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Inflammatory Compound Correlation
with other Inflammatory Compound
Maternal IL-10
Maternal IL-10: Infant IL-1β
Maternal IL-10: Infant IL-2
Maternal IL-10: Maternal IL-1β
Maternal IL-10: Maternal IL-2
Maternal IL-10: Maternal IL-8
Maternal IL-10: Maternal TNF-α
Maternal IL-1β
Maternal IL-1β: Maternal IL-10
Maternal IL-1β: Maternal IL-2
Maternal IL-1β: Maternal TNF-α
Maternal IL-2
Maternal IL-2: Maternal IL-10
Maternal IL-2: Maternal IL-1β
Maternal IL-2: Maternal TNF-α
Maternal IL-6
Maternal IL-6: Infant IL-6
Maternal IL-6: Infant IL-8
Maternal IL-6: Infant TNF-α
Maternal IL-6: Maternal IL-8
Maternal IL-6: Maternal Superoxide
Dismutase
Maternal IL-8
Maternal IL-8: Infant IL-6
Maternal IL-8: Infant IL-8
Maternal IL-8: Maternal IL-10
Maternal IL-8: Maternal IL-6
Maternal TNF-α
Maternal TNF-α: Infant IL-1β
Maternal TNF-α: Infant IL-2
Maternal TNF-α: Maternal IL-10
Maternal TNF-α: Maternal IL-1β
Maternal TNF-α: Maternal IL-2

rs (95% confidence interval)

0.250 (0.076 to 0.41)
0.231 (0.056 to 0.393)
0.610 (0.485 to 0.711)
0.507 (0.362 to 0.628)
0.215 (0.039 to 0.378)
0.548 (0.41 to 0.661)
0.610 (0.485 to 0.711)
0.750 (0.66 to 0.819)
0.644 (0.527 to 0.737)
0.507 (0.362 to 0.628)
0.750 (0.66 to 0.819)
0.647 (0.53 to 0.74)
0.387 (0.225 to 0.528)
0.349 (0.183 to 0.496)
0.231 (0.056 to 0.393)
0.896 (0.854 to 0.926)
0.734 (0.64 to 0.807)

0.341
0.219
0.215
0.896

(0.174
(0.043
(0.039
(0.854

to 0.489)
to 0.382)
to 0.378)
to 0.926)

0.266 (0.093 to 0.424)
0.234 (0.059 to 0.395)
0.548 (0.41 to 0.661)
0.644 (0.527 to 0.737)
0.647 (0.53 to 0.74)

Table 7: Correlation between maternal and infant cytokines (maternal). Spearman's
correlation coefficients (rs) were calculated for all inflammatory compounds in both infant
and maternal samples (N=122). Significantly significant (p <0.05) relationships are
included in this table. Other relationships were not statistically significant.
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Maternal and Infant Nutritional Compounds
In contrast to inflammatory compounds, in which infant measures tended to be
higher than the maternal levels, the levels of nutritional compounds were significantly
higher in mothers than in infants (Table 8; Figures 3-4). There were many statistically
significant correlations between the cytokines and nutritional compounds evaluated, most
frequently negative correlations between pro-inflammatory cytokines such as IL-1β and
IL-8 and anti-inflammatory nutritional compounds such the lycopenes and carotenes
(Table 9). However, these relationships were relatively weak (rs = -0.213 to -0.308; rs =
0.186 to 0.235). Additionally, there were several correlations that did not align with the
predicted axis of anti-inflammatory compounds decreasing pro-inflammatory compounds
and vice versa. These include infant TNF-α, which is a pro-inflammatory cytokine and was
positively associated with maternal cis-lycopene (rs = 0.186) and maternal total lycopene
(rs = 0.190), both anti-inflammatory nutritional compounds (Table 9). Maternal IL-6 and IL8, both potent pro-inflammatory cytokines, were most often found to be negatively
correlated with anti-inflammatory nutritional compounds. Maternal IL-6 and IL-8 are also
positively correlated with infant levels of these pro-inflammatory compounds (Table 7),
demonstrating the impact of maternal inflammation on the infant’s inflammatory state and
potential downstream effects of low levels of protective maternal nutritional compounds.
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Nutritional Compound
Infant samples
Lutein + Zeaxanthin
β-cryptoxanthin
trans-lycopene
cis-lycopene
Total lycopene
α-carotene
trans-β-carotene
cis-β-carotene
Total β-carotene
Retinol
δ-tocopherol
γ-tocopherol
α-tocopherol
Maternal samples
Lutein + Zeaxanthin
β-cryptoxanthin
trans-lycopene
cis-lycopene
Total lycopene
α-carotene
trans-β-carotene
cis-β-carotene
Total β-carotene
Retinol
δ-tocopherol
γ-tocopherol
α-tocopherol

Median (Q1, Q3)

Range

34.84 (26.23, 50.66)
17.22 (11.32, 25.49)
11.5 (8.30, 17.63)
12.74 (9.35, 18.58)
24.17 (17.26, 35.60)
3.72 (1.48, 6.65)
9.88 (5.18, 18.84)
0 (0, 3.03)
10.2 (5.18, 21.29)
166.76 (131.38, 208.1)
17.06 (12, 29.3)
207.22 (151.48, 275.3)
2941.48 (2192.66, 3654.24)

11.69-144.74
2.8-683.37
0.63-223.62
0.92-231.24
1.55-454.86
0-939.42
0-262.34
0-24.23
0-286.57
72.93-298.6
0-114.99
57.81-763.5
394.53-11904.2

216.51 (173.60, 273.11)
140.68 (91.17, 196.96)
309.7 (234.20, 410.73)
263.94 (210.59, 354.02)
574.83 (437.9, 764.01)
44.31 (27.34, 77.46)
166.26 (92.41, 286.79)
12.99 (7.71, 25.97)
176.33 (99, 312.80)
297 (240.65, 365.55)
110.07 (70.63, 182.21)
1,751.91 (1274.53, 2315.96)
18,893.1 (15,057.95, 21,194.87)

25.65-605.45
20.85-538.58
10.33-609.44
15.48-534.38
25.81-1128.24
2.38-1022.34
7.08-2792.48
0-210.6
7.08-3003.08
113.28-590.39
8.25-575.09
217.82-5,695.33
3,898.27-35,538.29

Table 8: Median infant and maternal nutritional compounds (mcg/L). N=122
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Maternal and Infant Nutritional Compounds
*
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*
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Figure 3: Maternal and infant nutritional levels. Median infant (black) and maternal
(grey) levels of nutritional compounds (mcg/L). N=122 * p < 0.001
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Maternal and Infant Tocopherols
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Figure 4: Maternal and infant tocopherols. Median maternal (grey) and infant (black)
levels of δ-, γ-, and α-tocopherols (mcg/L). N=122 * p < 0.001
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Cytokine: Nutritional Compound
Infant IL-2
Infant IL-2: Maternal α-tocopherol
Infant IL-8
Infant IL-8: Infant δ-tocopherol
Infant IL-8: Infant retinol
Infant TNF-α
Infant TNF-α: Maternal cis-lycopene
Infant TNF-α: Maternal total lycopene
Maternal IL-10
Maternal IL-10: Infant α-carotene
Maternal IL-1β
Maternal IL-1β: Infant β-cryptoxanthin
Maternal IL-1β: Maternal trans-β-carotene
Maternal IL-1β: Maternal total β-carotene
Maternal IL-2
Maternal IL-2: Maternal δ-tocopherol
Maternal IL-6
Maternal IL-6: Maternal δ-tocopherol
Maternal IL-6: Infant β-cryptoxanthin
Maternal IL-6: Infant cis-lycopene
Maternal IL-6: Infant total lycopene
Maternal IL-6: Maternal lutein +
zeaxanthin
Maternal IL-8
Maternal IL-8: Infant trans-lycopene
Maternal IL-8: Infant cis-lycopene
Maternal IL-8: Infant total lycopene
Maternal IL-8: Infant trans-carotene
Maternal IL-8: Infant total carotene
Maternal IL-8: Maternal trans-carotene
Maternal IL-8: Maternal cis-carotene
Maternal IL-8: Maternal total carotene

rs (95% confidence interval)
0.235 (0.06 to 0.396)
0.215 (0.039 to 0.378)
-0.213 (-0.377 to -0.037)
0.186 (0.009 to 0.352)
0.190 (0.013 to 0.356)
0.226 (0.05 to 0.388)
-0.218 (-0.381 to -0.042)
-0.224 (-0.386 to -0.048)
-0.220 (-0.383 to -0.044)
0.208 (0.031 to 0.372)
-0.231 (-0.393 to -0.056)
-0.239 (-0.4 to -0.064)
-0.228 (-0.39 to -0.052)
-0.234 (-0.395 to -0.059)
-0.224 (-0.386 to -0.048)

-0.254 (-0.413 to -0.08)
-0.308 (-0.461 to -0.138)
-0.296 (-0.45 to -0.125)
-0.267 (-0.425 to -0.094)
-0.263 (-0.421 to -0.089)
-0.206 (-0.37 to -0.029)
-0.267 (-0.425 to -0.094)
-0.213 (-0.377 to -0.037)

Table 9: Correlation between cytokines and nutritional compounds. Spearman's
correlation coefficients (rs) were calculated for all inflammatory and nutritional compounds
in both infant and maternal samples (N=122). Statistically significant (p <0.05)
relationships are included in this table. Other relationships were not statistically significant.
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Factors

Affecting

the

Correlation

between Inflammatory

and

Nutritional

Compounds

To address Specific Aim 3, we compared the inflammatory and nutritional
compounds in term and preterm infants, and then used the Fisher z-transformation to
determine if the correlation between cytokines and nutritional compounds were
significantly different between term and preterm infants. There was no statistically
significant difference between the inflammatory or nutritional compounds measured in
term versus preterm infants in this dataset (Tables 10-11). However, we found that the
positive correlation between anti-inflammatory infant IL-2 and anti-inflammatory maternal
α-tocopherol was significantly stronger in preterm (rs = 0.667) versus term infants (rs =
0.185) (Table 14). The correlation between maternal IL-2, which is anti-inflammatory, and
maternal δ-tocopherol, which is also anti-inflammatory, was also significantly different,
with a strongly negative correlation (rs = -0.661) in preterm infants and a weakly positive
correlation in term infants (rs = 0.308) (Table 14). None of the other correlations between
inflammatory and nutritional compounds, as identified on analysis of the entire dataset,
were significantly different between the term and preterm infants.

Given the large number of current or former tobacco users in this dataset (38.5%)
and increased inflammatory responses associated with prenatal tobacco use29-31, we also
compared the levels of inflammatory and nutritional compounds in samples from mothers
and infants with current or former tobacco use versus those without tobacco use. We found
that infants born to mothers with current or former tobacco use had significantly higher
levels of pro-inflammatory IL-8 (Table 10). Additionally, both infant and maternal samples
had higher levels of anti-inflammatory δ-tocopherol and lower levels of anti-inflammatory
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lutein, trans-β-carotene and total β-carotene than mother-infant pairs without tobacco use
(Table 11). We then used the Fisher z-transformation to determine if the correlation
between cytokines and nutritional compounds were significantly different between
samples with no prior tobacco use versus current or former tobacco use. We found that
the correlation between anti-inflammatory infant IL-2 and anti-inflammatory maternal αtocopherol in infants born to mothers without tobacco use (rs = 0.139) was significantly
different from that observed in infants born to mothers with current or prior tobacco use (rs
= -0.390) (Table 16). The correlation between pro-inflammatory infant TNF-α and antiinflammatory maternal cis- and total lycopene were also significantly different when
comparing results from mother with no tobacco use and those with prior or current tobacco
use (Table 16).
There were no statistically significant differences in the levels of inflammatory or
nutritional compounds in infants with or without prenatal complications. Given the small
number of participants with a prenatal complication (n=17, 13.9%), we did not evaluate
the difference in correlation between inflammatory and nutritional compounds in this
population versus those without complications. There were statistically significant
differences in the levels of several nutritional compounds in white versus non-white
participants (Tables 12-13). Therefore, race was included in the regression analyses
going forward.
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Overall
Infant samples
IL-10 21.29
IL-1β 8.52
IL-2 5.72
IL-6 13.72
*IL-8 12.99
TNF-α 52.12
Maternal samples
IL-10 14.78
IL-1β 6.3
IL-2 7.43
IL-6 11.05
IL-8 7.84
TNF-α 25.18

Term

Pre-term

Nonsmokers

21.29
8.53
5.77
13.72
11.86
51.36

21.52
8.385
5.62
18.80
22.05
58.27

21.29
8.60
6.82
14.92
11.12*
55.34

21.35
8.39
5.62
9.39
15.71*
51.21

14.62
6.07
7.43
10.695
7.36
24.31

22.485
7.16
7.95
46.16
8.58
32.72

14.87
7.135
7.51
10.695
7.49
24.7

14.78
5.35
5.84
14.79
8.17
25.405

Smokers

Table 10: Median differences in cytokines in infants and mothers based on
prematurity and tobacco use. Median inflammatory compound levels (pg/mL) in the total
participant dataset; term deliveries; pre-term (<37 weeks) deliveries; participants with no
evidence of maternal tobacco use (non-smokers); and participants with current or prior
tobacco use (smokers). Inflammatory compounds noted with * are statistically significant
with p <0.05 by Mann-Whitney test. There were no statistically significant differences
between the medians of term and pre-term deliveries. There were also no statistically
significant differences between the medians of deliveries with or without prenatal
complications.
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Nutritional
Compound
Infant samples
Lutein +
Zeaxanthin
β-cryptoxanthin
trans-lycopene
cis-lycopene
Total lycopene
α-carotene
trans-β-carotene
cis-β-carotene
Total β-carotene
Retinol
*δ-tocopherol
*γ-tocopherol
α-tocopherol
Maternal samples
*Lutein +
Zeaxanthin
β-cryptoxanthin
trans-lycopene
cis-lycopene
Total lycopene
α-carotene
*trans-β-carotene
cis-β-carotene
*Total β-carotene
Retinol
*δ-tocopherol
γ-tocopherol
α-tocopherol

Overall

Term

Pre-term

Nonsmokers

Smokers

34.84
17.22
11.5
12.74
24.17
3.72
9.88
0
10.2
166.76
17.06
207.22
2941.48

35.65
18.82
11.92
13.17
25.81
3.73
10.01
0
10.99
170.39
16.89
204.67
2916.82

32.14
13.865
10.84
11.38
22.275
3.68
7.75
0
8
131.29
18.86
255.905
3265.5

37.07
19.59
11.64
13.06
24.47
4.28
11.37
0
12.24
167.53
15.01*
172.16*
3062.24

31.82
15.26
11.325
12.375
23.385
3.18
7.695
0
8.17
162.64
21.735*
260.275*
2833.19

216.51
140.68
309.7
263.94
574.83
44.31
166.26
12.99
176.33
297
110.07
1751.91
18893.1

219.37
142.47
318.03
269.32
608.41
44.31
169.91
13.44
185.75
300.63
110.71
1651.54
18893.1

191.26
87.57
231.15
221.65
449.38
38.75
93.51
8.46
102.54
249.4
91.15
1851.08
19044.96

240.91*
145.56
310.88
264.44
568.95
47.93
200.69*
14.03
214.44*
300.46
94.50*
1520.59
19007.65

191.83*
123.54
304.96
261.8
584.67
37.66
137.42*
11.47
147.08*
292.75
137.79*
1978.86
18622.93

Table 11: Median differences in nutritional compounds in infants and mothers
based on prematurity and tobacco use. Median nutritional levels (mcg/L) in the total
participant dataset; term deliveries; pre-term (<37 weeks) deliveries; participants with no
evidence of maternal tobacco use (non-smokers); and participants with current or prior
tobacco use (smokers). Nutritional variables noted with * are statistically significant with p
<0.05 by Mann-Whitney test. There were no statistically significant differences between
the means of term and pre-term deliveries. There were also no statistically significant
differences between the medians of deliveries with or without prenatal complications.
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Overall
Infant samples
IL-10 21.29
*IL-1β 8.52
IL-2 5.72
IL-6 13.72
IL-8 12.99
TNF-α 52.12
Maternal samples
IL-10 14.78
IL-1β 6.3
IL-2 7.43
*IL-6 11.05
IL-8 7.84
TNF-α 25.18

White

Non-White

20.51
8.26*
5.65
12.12
11.96
51.5

24.43
13.35*
6.96
16.85
14.04
55.2

15.825
6.605
6.685
14.79*
8.95
25.775

12.58
5.78
7.985
9.12*
6.73
23.72

Table 12: Median differences in cytokines in infants and mothers based on
race/ethnicity. Median inflammatory compound levels (pg/mL) in the total participant
dataset; mothers identifying as white/Caucasian (n=85); mothers identifying as a
race/ethnicity other than white (n=37), including African American (19), Hispanic (7),
Asian/Pacific Islander (3), Native American (1), and other/unknown (7). Nutritional
variables noted with * are statistically significant with p <0.05 by Mann-Whitney test.
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Nutritional
Compound
Infant samples
Lutein +
Zeaxanthin
*β-cryptoxanthin
*trans-lycopene
*cis-lycopene
*Total lycopene
α-carotene
trans-β-carotene
cis-β-carotene
Total β-carotene
Retinol
δ-tocopherol
γ-tocopherol
α-tocopherol
Maternal samples
Lutein +
Zeaxanthin
β-cryptoxanthin
trans-lycopene
cis-lycopene
Total lycopene
α-carotene
trans-β-carotene
cis-β-carotene
Total β-carotene
*Retinol
δ-tocopherol
γ-tocopherol
α-tocopherol

Overall

White

Non-white

34.84
17.22
11.5
12.74
24.17
3.72
9.88
0
10.2
166.76
17.06
207.22
2941.48

33.23
15.615*
10.67*
12.115*
22.205*
3.945
9.8
0
10.135
167.145
16.655
197.15
2857.575

41.91
22.39*
14.03*
14.2*
30.64*
3.23
10.68
0
11.19
166.14
17.32
254.67
3167.8

216.51
140.68
309.7
263.94
574.83
44.31
166.26
12.99
176.33
297
110.07
1751.91
18893.1

203.1
134.97
294.31
249.42
544.85
47.31
174.8
13.75
187.79
309.1*
103.84
1623.74
18960.17

236.465
181.58
355.075
339.44
672.64
37.94
130.125
11.575
138.86
261.345*
138.74
1779.21
17522.94

Table 13: Median differences in nutritional compounds in infants and mothers
based on race/ethnicity. Median nutritional levels (mcg/L) in the total participant dataset;
mothers identifying as white/Caucasian (n=85); mothers identifying as a race/ethnicity
other than white (n=37), including African American (19), Hispanic (7), Asian/Pacific
Islander (3), Native American (1), and other/unknown (7). Nutritional variables noted with
* are statistically significant with p <0.05 by Mann-Whitney test.
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Cytokine: Nutritional Compound

Infant IL-2
Infant IL-2: Maternal α-tocopherol
Infant IL-8
Infant IL-8: Infant δ-tocopherol
Infant IL-8: Infant retinol
Infant TNF-α
Infant TNF-α: Maternal cislycopene
Infant TNF-α: Maternal total
lycopene
Maternal IL-10
Maternal IL-10: Infant α-carotene
Maternal IL-1β
Maternal IL-1β: Infant βcryptoxanthin
Maternal IL-1β: Maternal trans-βcarotene
Maternal IL-1β: Maternal total βcarotene
Maternal IL-2
Maternal IL-2: Maternal δtocopherol
Maternal IL-6
Maternal IL-6: Infant βcryptoxanthin
Maternal IL-6: Infant cis-lycopene
Maternal IL-6: Infant total lycopene
Maternal IL-6: Maternal lutein +
zeaxanthin
Maternal IL-6: Maternal δtocopherol

Term Infants
rs
(n= 108)

Preterm
Infants rs
(n= 14)

Fisher ztransformation

0.185

0.667*

-1.95*

0.224*
-0.174

0.332
-0.284

-0.37
0.37

0.263*

-0.154

1.34

0.284*

-0.176

1.48

0.192

0.538*

-1.28

-0.248*

0.082

-1.06

-0.265*

0.045

-1

-0.266*

0.091

-1.15

0.308*

-0.661*

3.51*

-0.254*

-0.200

-0.18

-0.177
-0.194
-0.201

-0.133
-0.133
-0.167

-0.14
-0.14
-0.11

-0.183

-0.417

0.082

Table 14: Difference in correlation between inflammation and nutritional
compounds based on prematurity. Spearman's correlation coefficients (rs) were
compared between samples in which the infant was born at term (n=108) versus preterm
(<37 weeks estimated gestational age; n=14) for all statistically significant relationships
identified on initial analysis. All statistically significant results (p<0.05) are indicated with *.
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Cytokine: Nutritional
Compound
Maternal IL-8
Maternal IL-8:
lycopene
Maternal IL-8:
lycopene
Maternal IL-8:
lycopene
Maternal IL-8:
carotene
Maternal IL-8:
carotene
Maternal IL-8:
carotene
Maternal IL-8:
carotene
Maternal IL-8:
carotene

Term Infants
rs
(n= 108)

Preterm
Infants rs
(n= 14)

Fisher ztransformation

Infant trans-

-0.262*

-0.178

-0.28

Infant cis-

-0.313*

-0.064

-0.82

Infant total

-0.310*

-0.134

-0.59

Infant trans-

-0.306*

0.002

-1

Infant total

-0.303*

-0.011

-1.02

Maternal trans-

-0.273*

0.182

-1.46

Maternal cis-

-0.286*

-0.108

-0.59

Maternal total

-0.271

0.099

-1.19

Table 15: Difference in correlation between inflammation and nutritional
compounds based on prematurity (maternal IL-8). Spearman's correlation coefficients
(rs) were compared between samples in which the infant was born at term (n=108) versus
preterm (<37 weeks estimated gestational age; n=14) for all statistically significant
relationships identified on initial analysis. All statistically significant results (p<0.05) are
indicated with *.
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Cytokine: Nutritional
Compound
Infant IL-2
Infant IL-2: Maternal α-tocopherol
Infant IL-8
Infant IL-8: Infant δ-tocopherol
Infant IL-8: Infant retinol
Infant TNF-α
Infant TNF-α: Maternal cislycopene
Infant TNF-α: Maternal total
lycopene
Maternal IL-10
Maternal IL-10: Infant α-carotene
Maternal IL-1β
Maternal IL-1β: Infant βcryptoxanthin
Maternal IL-1β: Maternal trans-βcarotene
Maternal IL-1β: Maternal total βcarotene
Maternal IL-2
Maternal IL-2: Maternal δtocopherol
Maternal IL-6
Maternal IL-6: Infant βcryptoxanthin
Maternal IL-6: Infant cis-lycopene
Maternal IL-6: Infant total
lycopene
Maternal IL-6: Maternal lutein +
zeaxanthin
Maternal IL-6: Maternal δtocopherol

NonSmokers
rs
(n= 74)

Smokers rs
(n= 47)

Fisher ztransformation

0.139

-0.390*

2.88*

0.295*
-0.283*

0.048
-0.145

1.33
-0.76

0.204

-0.184

2.05*

0.231

-0.169

2.12*

0.196

0.303*

-0.6

-0.225

-0.327

0.58

-0.253

-0.253

0

-0.255

-0.243

-0.07

0.229

0.330

-0.57

-0.410*

-0.023

-2.09

-0.314*
-0.336*

-0.026
-0.084

-1.56
-1.38

-0.315*

-0.06

-1.39

-0.268

-0.171

-0.53

Table 16: Difference in correlation between inflammation and nutritional
compounds based on tobacco use. Spearman's correlation coefficients (rs) were
compared between samples with no current or prior maternal tobacco use (n=74) and
those with current or prior maternal tobacco use (n=47) for all statistically significant
relationships identified on initial analysis. All statistically significant results (p<0.05) are
indicated with *.
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Cytokine: Nutritional
Compound
Maternal IL-8
Maternal IL-8:
lycopene
Maternal IL-8:
Maternal IL-8:
lycopene
Maternal IL-8:
carotene
Maternal IL-8:
carotene
Maternal IL-8:
carotene
Maternal IL-8:
carotene
Maternal IL-8:
carotene

NonSmokers
rs
(n= 74)

Smokers rs
(n= 47)

Fisher ztransformation

Infant trans-

-0.327*

-0.188

-0.78

Infant cis-lycopene
Infant total

-0.339*
-0.352*

-0.256
-0.264

-0.048
-0.51

Infant trans-

-0.262*

-0.305

0.24

Infant total

-0.249

-0.307

0.33

Maternal trans-

-0.230

-0.105

-0.67

Maternal cis-

-0.281*

-0.158

-0.67

Maternal total

-0.241

-0.110

-0.71

Table 17: Difference in correlation between inflammation and nutritional
compounds based on tobacco use (maternal IL-8). Spearman's correlation coefficients
(rs) were compared between samples with no current or prior maternal tobacco use (n=74)
and those with current or prior maternal tobacco use (n=47) for all statistically significant
relationships identified on initial analysis. All statistically significant results (p<0.05) are
indicated with *.
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Based on the differences observed in the correlations between inflammatory and
nutritional compounds based on prematurity and maternal tobacco use, we then used
multiple regression to identify the relative impact of prematurity and tobacco use, as
defined by current or former tobacco use, on this correlation. The cytokine and nutritional
compound levels were first log10 transformed to allow for analysis of normalized data and
Pearson

coefficients

were

calculated

for

all inflammatory-nutritional

compound

relationship identified as significant in Spearman correlation analysis. For all statistically
significant Pearson coefficients, multiple regression was performed with the outcome
defined as the cytokine of interest and the nutritional compound defined as the predictor.
Neither prematurity nor tobacco use were significant variables in any of the models. As
expected, for many pro-inflammatory cytokines (IL-1β, IL-6, and IL-8), there is a reduction
in the level of the pro-inflammatory cytokine relative to the level of the anti-inflammatory
nutritional compound (Table 18).
Our analyses demonstrated significant correlations between the inflammatory
outcome compounds, particularly IL-6 and IL-8, and several nutritional compounds. This
could reflect the multifactorial influence of these nutritional compounds on maternal and
infant inflammation. Therefore, the model for each of the cytokines with multiple significant
nutritional compounds associations was expanded to include each of the nutritional
compounds as potential variables in addition to prematurity, tobacco use, and non-white
race. When both cis- and total lycopene are included in the model, as well as tobacco
use, prematurity and non-white, neither nutritional compound is significant in the model
(Log10 Maternal IL-6 = 1.249 – 0.313*non-white race + 0.360*prematurity). However,
maternal IL-1β did retain an inverse relationship with maternal trans-carotene (Log10
Maternal IL-1β = 1.173 – 0.156*log10 maternal trans-carotene). Non-white race, tobacco
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use and prematurity were not significant in the maternal IL-1β regression model. Similarly,
maternal

IL-8 retained an inverse relationship with anti-inflammatory

nutritional

compounds (Log10 Maternal IL-8 = 1.667 – 0.29*log10 maternal cis-carotene –
0.291*log10 infant cis-lycopene). Non-white race, tobacco use and prematurity were not
significant in the maternal IL-8 regression model.
Association Between Inflammatory and Nutritional Compounds and Adverse Infant
Outcomes
A small number of infants included in this dataset (n=10) were diagnosed with
respiratory distress syndrome (RDS) in the neonatal period. These infants had significantly
higher infant IL-8 (with RDS 62.55 pg/mL; without RDS 11.75 pg/mL; p = 0.019), a potent
pro-inflammatory cytokine, and lower maternal cis-lycopene (with RDS 234.79 mcg/L;
without RDS 269.04 mcg/L; p = 0.022), an anti-inflammatory nutritional compound, than
those without respiratory distress syndrome. There were no other significant differences
in inflammatory or nutritional compounds between those with RDS versus those without
RDS. There were no other adverse infant outcomes reported with this study.
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Cytokine
Infant IL-8
Infant IL-8
Infant IL-2
Infant IL-2
Maternal IL-1β
Maternal IL-1β
Maternal IL-1β
Maternal IL-6
Maternal IL-6
Maternal IL-6
Maternal IL-8
Maternal IL-8
Maternal IL-8
Maternal IL-8
Maternal IL-8
Maternal IL-8
Maternal IL-8

Intercept

Nutritional Variable

3.495

-1.025*infant retinol

0.618

0.184*infant trans-lycopene

1.173
1.175

-0.156*maternal trans-carotene
-0.154*maternal total carotene

1.660
1.808

-0.404*infant cis-lycopene
-0.427*infant total lycopene

1.185
1.385
1.460
1.298
1.287
1.382

-0.243*infant α-carotene
-0.339*infant cis-lycopene
-0.324*infant total lycopene
-0.282*infant trans-carotene
-0.272*infant total carotene
-0.325*maternal cis-carotene

Table 18: Regression models for inflammation and nutritional compounds. Pearson
coefficients were calculated for all inflammatory-nutritional compound relationships
identified as significant on Spearman correlation analysis. For all statistically significant
Pearson coefficients, multiple regression was performed to identify the impact of
prematurity and of tobacco use (as defined by current or former tobacco use) on the
relationship between the inflammatory and nutritional variable. Neither prematurity nor
tobacco use were significant variables in any of the relationships observed.
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CHAPTER FOUR: DISCUSSION
The “first 1000 days” have the potential to lay the foundation for the rest of a child’s
life.7 Increased inflammation in the perinatal period has been associated with many
adverse outcomes with lifelong impact, including poor growth, atopic diseases such as
asthma,

and neurologic complications

such as cerebral

palsy8,9,18,32. A better

understanding of the relationship between inflammation and nutrition could identify key
strategies for supporting optimal maternal and infant nutrition. However, the relationship
between nutritional and inflammatory compounds in infants and mother in the peri-natal
period is not well-defined. In this study, we confirmed our hypothesis that there are
significant inverse relationships between anti-inflammatory nutritional compounds such as
carotenoids and pro-inflammatory cytokines such as IL-1β, IL-6, and IL-8. This suggests
that improving maternal and infant intake of carotenoids and other anti-inflammatory
nutritional compounds could significant decrease inflammation.
Nutritional compounds including retinol, lutein, β-cryptoxanthin, tocopherols,
lycopene and carotene were higher in maternal versus infant samples in this participant
group. The correlation between these anti-inflammatory nutritional compounds and proinflammatory cytokines IL-6, IL-8, and IL-1β suggest that nutritional interventions could be
used decrease perinatal inflammation in mothers and infants. This may be particularly
important in preterm infants and in pregnancies complicated by tobacco use, as evidenced
by the significant differences observed in these groups in this study (Tables 14-17).
Interestingly, we did not observe an positive correlation between anti-inflammatory IL-10
and anti-inflammatory nutritional compounds, suggesting that the decreased inflammation
observed is more attributable to direct effects on the pro-inflammatory cytokines rather
than a bolstering of anti-inflammatory cytokines.
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Our results demonstrate the complex interplay among pro- and anti-inflammatory
cytokines in the immune response, as well as the potential for multi-factorial influences on
immunity. It is promising that there was still a significant relationship between maternal
inflammatory cytokines IL-1β and IL-8, even with multiple factors taken into account in the
modeling, such as the role of other nutritional compounds, tobacco use, prematurity and
race. We observed a proportional decrease in maternal inflammatory cytokines with
increases in maternal trans-carotene and cis-carotene, as well as infant cis-lycopene.
Given the association in our results between maternal and infant inflammation, increasing
maternal levels of these carotenoids could therefore have significant impact on perinatal
inflammation and its myriad adverse consequences.
Carotenes, vitamins C, E and D have shown promise as an anti-inflammatory
compounds in a variety of adult disorders, including, prostate cancer and cardiovascular
disease21,33-39. However, these studies in infants are lacking and this area of investigation
has been highlighted as a key gap in pediatric knowledge by the National Institute of Child
Health and Human Development20. Carotenoids were noted in many of our analyses to
have significant protective potential. Carotenoids are vitamin-A related compounds,
including α-, β-, cis-, and trans-carotene, lycopene, lutein and β-cryptoxanthin, found
primarily in plant-based foods33,35. Many studies have shown that carotenoids may have
anti-inflammatory and antioxidant properties that impact human health and disease,
including in maternal-infant dyad studies such as this one.33-36 Plasma levels of
carotenoids in mothers are strongly related to the dietary intake of fruits and vegetables33,
making this an important target of both individual prenatal nutritional counseling as well
as large-scale programmatic strategies for optimizing prenatal nutrition.
Limitations of this study include the small sample size, particularly in regards to the
number of preterm mother-infant pairs enrolled. This may have limited our ability to detect
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significant differences in preterm infants. This pilot data will be expanded to a larger
sample size in the future to further evaluate the impact of prematurity and tobacco use on
the relationship between inflammation

and nutrition. Additionally, as this is an

observational study, the effects observed here may be due to another variable that was
not included in our data analysis. Inflammation is a multifactorial process and controlled
studies will be essential for demonstrating definitive links between higher levels of
carotenoids and decreased inflammation. Long-term studies will also be needed to
evaluate the impact of these interventions on child development and health.
Developing nutritional approaches to mitigating inflammation offers the opportunity
for both pre- and post-natal interventions. The results of this study are particularly
promising in highlighting the relationship between maternal anti-inflammatory nutritional
compounds and infant pro-inflammatory cytokines. The interactions between nutritional
status and inflammation represent a potential therapeutic target for reducing inflammation
in term and pre-term infants, who may be particularly susceptible to inflammation during
the period of rapid neurodevelopment in infancy7-9. Additionally, this information could lead
to earlier identification of infants at risk for neurodevelopmental disorders or other adverse
inflammatory outcomes due to dietary insufficiencies during these crucial periods. Early
identification could guide more aggressive or specifically targeted behavioral therapies in
addition to nutritional supplementation to improve overall clinical outcomes. Thus, defining
the factors that shape the inflammatory response in infants has the potential to significantly
impact the health of neonates and infants in the US and throughout the world, particularly
in developing countries.
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